Human recombinant insulin refers to the manufacture of insulin through genetic engineering by inserting the human insulin gene into bacteria or yeast to produce human insulin. Human recombinant insulin is used for the treatment of diabetes. It has several advantages over animal insulin as it is associated with fewer allergic reactions or side effects. The rising prevalence of diabetes across the globe due to sedentary lifestyle and obesity is a major factor driving the demand for recombinant insulin. According to the International Diabetes Federation, approximately 537 million adults were living with diabetes in 2021 and the figure is anticipated to rise to 784 million by 2045.

The Global Human Recombinant Insulin Market is estimated to be valued at US$ 47926.32 Bn in 2024 and is expected to exhibit a CAGR of 12% over the forecast period 2024 to 2030.

Key Takeaways
Key players operating in the Human Recombinant Insulin market are Eli Lilly and Company, Novo Nordisk A/S, Sanofi, Tonghua Dongbao Pharmaceutical Co., Ltd., Merck & Co. and Julphar. Eli Lilly and Company holds the largest market share owing to its popular recombinant insulin brands such as Humalog.

The growing prevalence of diabetes across the globe coupled with the rising geriatric population which is more prone to developing diabetes are some of the major factors fueling the demand for recombinant insulin. According to the World Health Organization, the number of people with diabetes is projected to rise from 422 million in 2014 to 592 million by 2035.

Technological advancements are leading to the development of newer formulations of recombinant insulin which are safer and provide better glycemic control. Manufacturers are focusing on developing fast-acting and long-acting recombinant insulin to suit the insulin requirement of patients. This is expected to boost the growth of the market during the forecast period.

Market Trends
One of the key trends gaining popularity in The Recombinant Insulin Market is the development of concentrated insulin formulations. Concentrated insulins allow for the administration of smaller volumes but with higher doses, reducing injection volumes. Furthermore, manufacturers are developing inhaled formulations of insulin to provide non-invasive therapy and improve patient adherence to treatment.

Growing adoption of combination insulin therapies using two different insulins administered together. Combination insulins provide enhanced glycemic control by mimicking the body's natural insulin release better than single insulin formulations. This trend is expected to continue driving the recombinant insulin market.

Market Opportunities
Increasing focus on emerging economies in Asia Pacific and Latin America represents major growth opportunities. Rapid economic development and improving access to healthcare in these regions will boost recombinant insulin uptake. Moreover, the large diabetic patient pool coupled with low awareness and treatment rates currently offers huge untapped market potential.

Advancements in drug delivery technologies provide opportunities for development of novel recombinant insulin delivery modes beyond conventional syringes and pens. Devices such as injectable patches, inhaled insulins and closed-loop insulin delivery systems could drive future market revenue if launched successfully.

Impact of COVID-19 on Human Recombinant Insulin Market

The COVID-19 pandemic has negatively impacted the growth of the human recombinant insulin market. During the peak of the pandemic, lockdowns and physical distancing norms disrupted the supply chain and production of insulin. Patients also delayed or avoided non-emergency medical visits and treatments due to fear of contracting the virus from healthcare facilities. This adversely affected insulin demand and sales during 2020. However, as the pandemic is now being brought under control through vaccination programs, the market is gradually recovering.

The demand for insulin is expected to rise post-pandemic as patients resume their regular treatments and healthcare seeking behavior returns to normal levels. Manufacturers are also focusing on expanding production capacities and building resilient supply networks to tackle future disruptions. Governments worldwide are incentivizing investments in biologics and biosimilars production to reduce reliance on imports. Digitization of healthcare systems through teleconsultations and online prescriptions is also supporting continued access to insulin for patients. While short-term challenges persist, the long-term outlook for the market remains positive due to the growing prevalence of diabetes globally.

North America accounts for the largest share in the human recombinant insulin market in terms of value. This is attributed to the rising incidence of diabetes, growing obesity rates, aging population prone to chronic diseases, and high healthcare spending in the US and Canada. The availability of favorable reimbursement policies for insulin therapies also contributes to the high market concentration in the region.

The Asia Pacific region is expected to be the fastest growing market for human recombinant insulin. This is due to the increasing awareness about diabetes management, growing affordability of insulin drugs, expansion of health insurances, and rising healthcare investments in major APAC countries such as China and India.

Get more insights on this topic: https://www.insightprobing.com/human-recombinant-insulin-market-analysis/